In last trading session, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) saw 2.42 million shares changing hands with its beta currently measuring 0.44. Company’s recent per share price level of $2.54 trading at -$0.02 or -0.78% at ring of the bell on the day assigns it a market valuation of $394.08M. That closing price of MREO’s stock is at a discount of -97.64% from its 52-week high price of $5.02 and is indicating a premium of 37.8% from its 52-week low price of $1.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.0 million shares which gives us an average trading volume of 1.42 million if we extend that period to 3-months.
For Mereo Biopharma Group Plc ADR (MREO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.01 in the current quarter.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Upright in the red during last session for losing -0.78%, in the last five days MREO remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $2.54 price level, adding 1.93% to its value on the day. Mereo Biopharma Group Plc ADR’s shares saw a change of -27.43% in year-to-date performance and have moved 19.25% in past 5-day. Mereo Biopharma Group Plc ADR (NASDAQ:MREO) showed a performance of 8.09% in past 30-days. Number of shares sold short was 6.54 million shares which calculate 4.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7.5 to the stock, which implies a rise of 66.13% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -57.48% in reaching the projected high whereas dropping to the targeted low would mean a loss of -57.48% for stock’s current value.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.89M for the same. And 7 analysts are in estimates of company making revenue of 4.93M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.82% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 26.19% while estimates for its earnings growth in next 5 years are of 17.79%.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Insiders are in possession of 0.96% of company’s total shares while institution are holding 75.04 percent of that, with stock having share float percentage of 75.77%. Investors also watch the number of corporate investors in a company very closely, which is 75.04% institutions for Mereo Biopharma Group Plc ADR that are currently holding shares of the company. RUBRIC CAPITAL MANAGEMENT LP is the top institutional holder at MREO for having 15.31 million shares of worth $55.11 million. And as of 2024-06-30, it was holding 2.1506 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 11.79 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.6566 of outstanding shares, having a total worth of $42.45 million.
On the other hand, Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and iShares Trust-iShares Genomics Immunology and Healthcare ETF are the top two Mutual Funds which own company’s shares. As of Feb 28, 2025 , the former fund manager was holding 759.1 shares of worth $1.93 million or 0.10% of the total outstanding shares. The later fund manager was in possession of 242.04 shares on Mar 31, 2025 , making its stake of worth around $0.61 million in the company or a holder of 0.03% of company’s stock.
